of the development cohort, while dedicated diagnostic arrays containing subtype related gene and normalization probes were used for the validation cohort. Molecular subtype classification by the developed SSP is based on three distinct gene expression signatures representative for the molecular subtypes. These three distinct gene signature were identified using the original hierarchical clusters on the 188 tumor samples 1 and by performing a pair-wise Student T-test analysis for the most differentially expression genes between the three clusters (i.e. A-type versus B-and C-types; B-type versus A-and Ctypes; and C-type versus A-and B-types). This T-test analysis was performed within a 10-fold cross validation procedure and genes were ranked according to their Student's T-test statistics. The top-ranked gene lists across the multiple cross validation iterations were combined, resulting in a final gene selection of genes commonly (>50%) used in the cross
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Roepman P et al II validation iterations: 32 genes for A-type, 53 genes for B-type and 102 genes for C-type (Table 2) Next, we have used these three gene signature to develop a centroid based SSP that scores each sample for its association with the three subtypes. Normalized gene expression levels of individual samples were compared to each of subtype specific gene centroids (Pearson correlation) and used to determine the most representative subtype (A-, B-or C-type). This final verdict of this 3-way classification system was based on the highest correlation score using the formula below was derived by optimizing the SSP classification accuracy against the original hierarchical clustering (optimal accuracy was 97%). The developed classification methods for the CRC molecular subtypes is very similar to the one used in the BluePrint breast cancer classification model. 
MSI assessment (by hospital)
MSI-status for patients in the development cohort was defined by immunohistochemical staining of FFPE slides for the markers MLH1 and PMS2. MSI-status in patients from the For all patients from the German hospital. Genomic DNA of tumor and corresponding normal colon mucosa were analyzed for microsatellite instability using the Qiagen® Type-it Microsatellite PCR Kit (Qiagen GmbH, Hilden, Germany). Two mononucleotide and three dinucleotide Bethesda markers (BAT25, BAT26, D2S123, D5S346, and D17S250) were investigated. A tumor with five normal markers was defined as microsatellite stable (MSS).
Irregularity in one marker was defined as low grade microsatellite instability (MSI-L), irregularity in two or more markers was defined as high grade microsatellite instability (MSI-H).7 Patients with low grade MSI (MSI-L) were classified as MSS for all analysis.
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MSI signature readout
The development of the MSI/dMMR signature is described in more detail in Ref 8. Shortly, expression measurements were normalized (lowess normalization) and log-ratios were used for identification of genes that were associated with the tumors' MSI status (based on two-sided Student's t-test). We used a 10-fold cross validation (CV10) procedure that was repeated a thousand times to determine classification performance and for robust gene 
